<p>British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug</p><ul><li><p><a href="https://www.theguardian.com/business/live/2026/oct/28/john-healey-budget-standing-charges-gas-city-bonds-pound-latest-news-updates">Business live – latest updates</a></p></li></ul><p>Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker vaccine sales, restructuring charges and its overall outlook.</p><p>Britain’s second-biggest pharmaceutical company reported a 19% decline in pre-tax profit to £1.9bn in the July to September quarter and £318m of restructuring charges, with more to come.</p> <a href="https://www.theguardian.com/business/2026/oct/28/gsk-shares-dive-as-weaker-sales-and-mounting-costs-unnerve-investors">Continue reading...</a>
World
GSK shares dive as weaker sales and mounting costs unnerve investors
<p>British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drug</p><ul><li><p><a href="https://www.theguardian.com/business/live/2026/oct/28/john-healey-budget-standing-charges-gas-city-bonds-pound-latest-news-updates">Business live – latest updates</a></p></li></ul><p>Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker vaccine sales, restructuring charges and its overall outlook.</p><p>Britain’s second-biggest pharmaceutical company reported a 19% decline in pre-tax profit to £1.9bn in the July to September quarter and £318m of restructuring charges, with more to come.</p> <a href="https://www.theguardian.com/business/2026/oct/28/gsk-shares-dive-as-weaker-sales-and-mounting-costs-unnerve-investors">Continue reading...</a>